J&J to include prices in drug ads on TV

US multinational Johnson & Johnson has announced that it will include the price of its medicines in TV commercials for its drugs.
The world’s largest healthcare company will become the first to take action after President Trump called on pharma firms to include prices in adverts of drugs on TV.
The healthcare conglomerate will include both the list price of the products being advertised as well as the out-of-pocket costs the consumer should expect to pay.
The move however comes after a study published in JAMA Internal Medicine found that patients were just as likely to be interested in a drug with a high list price, as long as they did not have to pay high out-of-pocket costs.
Nevertheless, HSS Secretary Alex Azar praised the firm in stating: “We commend Johnson & Johnson for recognizing the value of informing consumers about list prices and for doing so voluntarily. We call on other manufacturers to follow their lead.”
Ads for J&J’s blood thinner Xarelto, the company’s most frequently prescribed medicine, will be the first to include prices in TV ads. The treatment costs between $450 and $540 a month.
Louis Goss
- Login or register to post comments
- Printer-friendly version
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
- J&J's CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma
- J&J must pay $572 million for fuelling opioid crisis in Oklahoma, judge says
- Trump says executive order will ensure US will pay lowest prices in the world for drugs
- J&J bows to PETA pressure and drops forced swim tests in mice
- Pharma chiefs will testify at Senate hearing on rising drug prices